reason report
bottom line conjunct recent publish leerink
outlook report link link provid granular
preview seven near commerci stage compani
coverag includ updat thought upside/downsid
potenti stock come month introduc
quarterli financi estim well model updat
remain favorit mid-cap stock view
provid compel risk/reward ratio
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
mean consensu ev sale multip
leerink partner estim factset
note figur except per share data
takeaway share predominantli driven partner celg op
approv idhifa nda submiss agio ivosidenib relapsed/refractori r/r aml
addit regul provid easi guidanc path registr ultra-rar
pyruvate-kinas defici pk appear execut year sever pivot trial
enrol plan remain posit innov platform
support compani close collabor celg view idh inhibitor opportun
aml could increment larger current anticip investor earlier stage
program provid sourc potenti upsid longer term updat pt
function minor model tweak post-ash revis assumpt well lower peak tax
market opportun agio idh inhibitor aml could bigger current
anticip visibl plan phase trial front-lin fit aml patient idhifa
ivosidenib partner celg commit view potl sourc increment upsid
earli phase data recent present link evalu combin idhifa
ivosidenib standard care chemotherapi view support plan phase trial
front-lin aml present first result phase i/ii dose-escal trial
evalu combin either ivosidenib idhifa either vidaza elderly/unfit patient
chemotherapi young/fit patient respect celg enrol confirmatori phase
trial idhentifi r/r aml addit on-going phase trial ivosidenib vidaza
agil front-lin elderli patient also recent submit nda applic ivosidenib
r/r aml set stage potenti approv commerci launch import read-
recent mylotarg fda approv accord medacorp kol spoke
event free surviv ef accept regulatori endpoint front-lin aml oppos
overal surviv could potenti acceler to-market time agent
impress toler profil idh inhibitor also support combin novel agent
exampl abbv op venclexta could form basi addl partnership current
model us ww ivosidenib peak sale aml well peak idhifa
royalti celg contribut valuat
solid tumor upsid current idh estim given lower level visibl updat result
glioma expans cohort on-going ph trial ivosidenib advanc solid
tumor present sno meet novemb ph dose-escal ph studi
back-up pan-idh inhibitor idhm posit glioma complet enrol first preclin
data idhm solid hematolog malign present aacr-nci-eortc
confer octob base data plan initi periop window studi
ivosidenib low grade glioma investig effect brain tumor tissu
without particip celg addit random phase trial ivosidenib icca
enrol complet expect
pivot trial pkd expect initi base easi fda guidanc
base input form us eu regulatori agenc plan initi two global pivot trial
evalu adult pyruv kinas pk defici random placebo-control
trial non-transfus depend ntd patient primari endpoint studi
proport patient achiev least increas hemoglobin month single-
arm trial pkd patient transfusion-depend td primari endpoint reduct
transfus burden month trial includ individu dose-titr phase optim
dose patient pivot trial exclud enrol patient less like respond
therapi non-missens pk mutat homozyg mutat
roughli pkd patient popul base data natur histori studi
believ trial could complet product launch like current
conserv assum probabl success po contribut valuat
mtap inhibitor key sourc upsid valuat longer term mtap
methylthioadenosin phosphorylas pathway program part agio co-develop co-
commerci agreement celg focus metabol immuno-oncolog
world-wide cost profit share make mtap program particularli interest
mtap-delet present approxim cancer discov novel inhibitor
elegantli address pathway first develop candid recent identifi
plan file ind year-end
arri mp busi year ahead what meaning catalyst
takeaway arri share volatil close specul drove
much volatil earli well cotel trial success braf melanoma
disappoint nra melanoma phase initi braf colorect cancer
anoth event-rich year arri expect share remain volatil upcom event
includ top-lin result rhhbi trial line approv
launch binimetinib/encorafenib braf melanoma potenti regulatori feedback
potenti beacon-crc phase trial chang phase result azn mp selumetinib
differenti thyroid cancer dtc expect updat pt rate
complet posit astra result estim arri share could trade high-teen
insignific chang beacon-crc timelin think arri could pull-back high singl
digit arri trade high end rang peer mean
braf key valu driver arri view arri start enrol phase
beacon-crc trial evalu arri encorafenib binimetinib combin
erbitux braf colorect cancer patient phase trial support posit phase data
evalu erbitux encorafenib doublet triplet binimetinib expect complet
overal surviv os primari endpoint interim analysi current includ
statist analysi plan unlik indic arri ahead competit braf
melanoma phase data present date impress management indic
evalu differ option acceler regulatori timelin incorpor interim analysi
chang primari endpoint success think would view posit
investor braf current contribut arri valuat assum
po us launch driven updat ww peak sale forecast us
assum peak market share braf mcrc respect
magnitud braf melanoma oppti less certain pdufa date binimetinib/encorafenib
braf melanoma june support strong columbu phase data think approv
wide expect investor size commerci opportun braf melanoma
howev remain area debat market posit increment differenti
approv agent accord medacorp kol spoke past lower progress
rate due improv adjuv treatment commerci headwind view current model
us peak sale braf melanoma assum approv probabl peak
market share arri contribut arri pt
rhhbi cotel trial result could read arri current
includ potenti binimetinib sale combin inhibitor model given earli
develop stage limit clinic proof-of-concept repres potenti sourc long-term
upsid price target recal arri togeth mp mp op recent
initi phase trial evalu combin binimetinib io agent collabor
across variou tumor type result roch phase trial colorect cancer
expect could potenti provid clinic valid concept combin mek
inhibitor inhibitor least colorect cancer whether result would read though
posit indic lung cancer remain unclear roch thu far
report result phase ib lung cancer cohort highlight cautious
optimist po imblaz
azn selumetinib minor valu driver mek inhibitor selumetinib licens
azn subsequ partner w/ current sever clinic trial differenti thyroid
cancer dtc neurofibromatosi type repres two indic visibl best
fact azn expect releas top-lin result phase astra dtc trial base
updat model think selumetinib address potl ww peak oppti assum
po trial togeth po selumetinib royalti current contribut
limit visibl proprietari earli stage pipelin arri visibl earli stage program
includ inhibitor inhibitor opportun still
unclear view recent data cabiralizumab certainli provid efficaci signal
pancreat cancer daiichi/plexxicon recent abandon develop tki howev
less enthus oppti rare lmn-dca view potenti spin-off
op investor focu ovarian rubraca deliv prostat
takeaway volatil close year event posit
ariel phase trial result rubraca ovarian cancer oc mainten drug
demonstr strong profil rel competitor drug lynparza zejula stock sold
though driven predominantli competit concern oc slower initi launch
rubraca anticip share trade signific discount peer mean
fda approv larg oc mainten set april pdufa
well phase ii interim data pivot phase ii trial metastat castrate-
resist prostat cancer mcrpc import catalyst stock ultim think
opportun parp inhibitor span sever cancer type includ oc mcrpc bladder breast
other view well posit partner address oppti
pt assum long-term market share ovarian cancer well
probability-adjust estim prostat breast bladder cancer think share
could end near high around bullish scenario acceler commerci
uptak ovarian cancer posit interim data bearish scenario lower market
share oc prostat failur would result pt
one-third market share ovarian cancer still plausibl scenario view recent
medacorp ovarian cancer survey point bullish pictur regard initi uptak overal
opportun parp inhibitor ovarian cancer estim peak us
faster-than-expect uptak parp mainten natur pose near-term competit
headwind rubraca current approv treatment set believ well
understood reflect stock street consensu estim come
hand think rubraca well posit captur market share larg
mainten categori pend approv april base strong trial result
physician particip recent post-lynparza approv survey continu view three
lead parp rubraca zejula tsro lynparza azn mp compar nuanc
differ product profil expect major impact choic agent
think like result market split larg mainten market
prostat cancer could emerg major opportun parp inhibitor
indic longer term upsid continu maintain leadership posit prostat
cancer mcrpc next larg commerci opportun parp inhibitor interim result
pivot trial expect like esmo accord management
anticip snda file acceler approv pathway mcrpc upon complet
trial believ mcrpc repres initi us market opportun
conserv attribut peak market share like reach market
first clinic collabor op also posit compani well rel
competitor captur market share ovarian breast prostat cancer view particular
parpi combin inhibitor prove synergist competitor data recent
present san antonio breast cancer symposium provid valid
potenti parp breast cancer get credit point rubraca
combin trial w/ set initi
mp cotel updat kick-off busi year alreadi
takeaway share doubl valu cabometyx exceed
launch expect rcc label expans opportun product rcc
play success trade market cap mean ev/
consensu multipl think stock present fairli valu face event-rich
particularli first half keep stock radar mani investor
event includ present full celesti phase result cabometyx
cotel phase trial result colorect cancer addit competit
environ rcc main target market cabometyx remain flux sever
competitor event expect throughout base updat sum-of-part dcf analysi
see upsid bull-cas scenario downsid bearish scenario
next month rate remain market perform updat pt
full celesti phase result asco-gi jan provid insight
competit posit cabometyx previous announc
celesti trial met primari endpoint overal surviv os manag indic
cabometyx provid statist signific also clinic meaning improv os
compar placebo patient advanc nexavar-experienc patient big
cabo market potenti remain uncertain light chang competit environ
full trial result asco-gi includ median os median safety/toler
import data point determin drug posit rel agent recent
approv pend set bayer stivarga opdivo eisai lenvima mrk
keytruda model current reflect base case scenario assum peak market share
forecast ww cabometyx peak sale us row
ipsen takeda incorpor new higher price assumpt drug base exel
recent price growth rcc current contribut valuat
cabometyx efficaci significantli exceed data report bayer stivarga month
month without much addit toxic make prefer second line
treatment market share model indic npv upsid bear case scenario
product profil less compel vs competitor dcf indic npv
cotel could potenti valu driver probability-of-success
modest view rhhbi guid releas top-lin result phase trial
evalu cotel combin tecentriq vs stivarga line later metastat colorect
cancer patient trial base result form phase ib trial combin
result first present indic orr combin mpf
month os compar favor stivarga achiev
orr month median month median os intrigu phase trial
rel small addit clinic data melanoma patient
gener clearli indic synergist activ combin mek inhibit nsclc
data present addit patient phase kra relev
uncertain rhhbi didnt requir kra mutat phase sampl size kra post-hoc
subgroup analysi may small reach statist signific current assum
probabl success contribut valuat trial success add failur
remov pt potenti posit result read addl indic
rhhbi conduct phase ii trial pancreat cancer tnbc see addl upsid
rcc market evolv current well posit set
front line market pois chang rapidli beyond rhhbi recent announc
posit rhhbi phase trial result rcc patient data like
asco-gu mid-februari expect approv launch opdivo/yervoy combo
rcc april pdufa date aveo expect report top-lin phase trial result
tivozanib rcc trial may also result file front-lin set
expect report top-lin result javelin phase trial combin
avelumab inlyta year-end updat phase ib data provid basi recent receiv
breakthrough therapi design btd present februari evolv
landscap rcc affect cabometyx growth could sourc uncertainti investor
well posit rcc long-term result phase trial
rcc compar opdivo yervoy vs sutent expect rcc current
contribut pt assum market share
rcc assum low double-digit quarterli sale growth rcc forecast could move
less bullish growth assumpt respect
indic potl sourc upsid longer term recent initi phase trial
partner rhhbi evalu cabometyx combin tecentriq multicent phase
open-label studi divid two part dose-escal phase expans cohort phase
four expans cohort evalu includ patient nsclc rcc
urotheli carcinoma uc dont expect meaning data emerg
what stock what upside/downsid next month base updat
sum-of-part dcf analysi think share current fairli valu assum
continu doubl digit quarterli cabometyx sale growth rcc support modest uptak
contribut bladder cancer po mtc well pos-adjust
cotel sale bull-cas scenario think could trade year
model bullish outlook cabometyx rcc assum cotel success
hand lower growth assumpt rcc due competit less assum
differenti cabometyx well cotel failur result downsid valuat
op binari event approach what epacadostat worth
takeaway trade high fuel euphoria around inhibitor
epacadostat hope low investor becom skittish ahead
phase trial readout swing market cap trade near low
think risk/reward own stock trial result melanoma quit favor
trial fail think stock worth downsid current valuat think could
trade best-cas scenario repres upsid plausibl base case could still
mean upsid beyond epacadostat think investor larg discount
baricitinib olumi potenti ra inflammatori diseas psoriat arthriti atop
dermat fda action date expect june follow partner lli mp recent nda re-
submiss jakafi phase trial result gvhd repres anoth potenti albeit small valu
driver
mother binari expect result incy/mrk
trial advanced/metastat melanoma could either valid disprov mechan
inhibit target oncolog trial outright fail think valu could justifi
inci base busi base sop-dcf valuat consist jakafi/jakavi
baricitinib iclus cash succeed upsid depend
data combin keytruda epacadostat look compar better term
efficaci seen opdivo yervoy think share could trade high
bull case scenario result posit clearli inferior yervoy
combin think investor intens debat valu epacadostat io treatment
paradigm one hand good safeti profil epacadostat could still prove benefici yervoy
evalu tripl combin exampl inci nsclc trial earlier stage
patient stage nsclc adjuv melanoma hand question whether
melanoma data translat indic debat base case scenario view
could see stock settl around think justifi global
us epacadostat peak sale current model po includ
contribut indic contribut pt
jakafi sale outperform street consensu expect updat jakafi
us sale estim street consensu current model annual
us sale growth vs street consist underestim jakafi sale potenti
row royalti enjoy monopoli market posit myeloprolif diseas mpn
myelofibrosi polycythemia vera two indic partial penetr price
power strong jakafi consensu exampl
respect begin year ultim report
expect gvhd repres potenti upsid opportun view
increas scrutini around co-pay assist fund program potenti headwind top-lin
result trial acut steroid-refractori gvhd expect essenti
baricitinib expect low us approv june potenti sourc upsid baricitinib
royalti consensu declin sinc obtain complet respons letter april
analyst includ us push potenti us launch ra year well
lower forecast said mp recent resubmit new drug applic nda
baricitinib rheumatoid arthriti fda late decemb significantli ahead
late june phase trial psoriat arthriti atop dermat on-going track
initi think jak inhibitor market inflammatori diseas ultim exceed
baricitinib abl captur piec market context think label languag
ra particular inclus efficaci qd dose label repres posit
catalyst stock baricitinib current contribut pt assum pos-
adjust ww sale ra
earli pipelin stori view current includ valu pt
inci oncolog portfolio outsid jakafi iclus epacadostat advanc agent
develop capmatinib select inhibitor c-met licens nv
anticip submiss nda applic nsclc right receiv double-
digit royalti capmatinib sale inci licens op small molecul
select arginas inhibitor could gener investor interest phase dose-escal clinic
trial patient solid tumor initi sept variou dose-expans cohort plan
includ singl agent cohort nsclc tumor high mdsc well variou
combin cohort opdivo inhibitor program potenti pivot
phase ii trial evalu drug genet select patient metastat bladder cancer
cholangiocarcinoma rare myeloprolif neoplasm result expect
still evalu optimum dose schedul inhibitor citadel trial
evalu drug across differ non-hodgkin lymphoma subtyp drug within io
portfolio evalu combin inhibitor recent licens op
op execut matter proof critic wrong
takeaway share high back posit
nerlynx data earli breast cancer posit fda panel fda-approv broad
label well disappoint competitor data rhhbi aphil trial repres best case
scenario nevertheless share still trade peer novemb high
investor becom nervou around launch prospect peak opportun nerlynx
posit sinc believ stock doesnt adequ repres nerlynx potenti earli
stage breast cancer phase trial result nala metastat patient well potl eu
approv repres near-term catalyst pt conserv base
peak market share adjuvantli treat breast cancer patient also includ
pos-adjust sale metastat patient po adjust peak sale bear case scenario
poor launch eu approv nala fail think share could trade success launch
 meet street consensu posit nala result eu approv could support
nerlynx meet street consensu current nerlynx street consensu
accord factset vs estim bullish nerlynx launch peak
opportun base feedback medacorp kol well recent medacorp physician
survey indic broad use drug across variou subgroup node /- hr /- patient
consist broad product label natur concern note well-known
diarrhea side effect drug howev physician expect complianc rate consist
better seen extenet phase trial competitor roch perjeta
recent fda-approv seem benefit greater physician comfort -- like due current use
neoadjuv set -- think nerlynx continu look well-posit competit given
drug work best patient perjeta outcom worst hr patient
make treatment decis inform physician patient rel
straightforward may need aid strong sale effort commerci tram
consist perjeta label restrict patient high risk recurr
roch press releas defin lymph node-posit hormon receptor-neg
breast cancer consensu consist estim
key catalyst eu-approv nala phase trial result ema scientif
advisori group sag oncolog provid opinion clinic aspect market
author applic nerlynx meet held januari management
expect chmp opinion month follow sag meet mid-februari row revenu
current contribut price target yet final commerci
strategi europ hous launch eu partnership sale compani three
possibl commerci option accord manag current assum commerci eu
partnership plausibl base-cas scenario result phase nala trial expect
second pivot phase trial neratinib line metastat breast cancer
set complet patient accrual top-lin result expect nala double-
blind control trial compar nerlynx combin capecitabin xeloda vs tykerb lapatinib
combin xeloda patient trial conduct spa agreement fda
co-primari endpoint os plan submit nda base
result posit current model po pos-adjust peak sale
met breast cancer patient view trial rational base nerlynx well-
known superior mechan activ vs tykerb strong approv neratinib could also benefit
activ patient metastas underserv patient group accord kol
spoke serv well current drug particular potl futur
compendia list metastat breast cancer metastas could support uptak metastat
set drug approv base nala trial result
op investor still digest result succeed
takeaway share volatil end year flat stock reach
high earli year sold follow releas top-lin result
reach low august stock partial recov sinc broaden late
stage pipelin advanc two addit program pivot trial enfortumab
vedotin urotheli cancer tisotumab vedotin cervic cancer result
phase trial adcetri peripher cell lymphoma first result
emerg pipelin multipl myeloma key catalyst one interest theme could
combin adc inhibitor sever trial on-going result hl recent
present look impress
model adcetri us sale growth vs recent label expans
ctcl well uptak front-lin hl key sale growth driver said latter like
take full effect forecast street consensu assum
growth potenti earli inclus adcetri nccn guidelin well off-label use
combin opdivo driven impress phase i/ii data present sourc upsid
near-term forecast wherea less expect use front-lin hl repres downsid long
term model bullish scenario us peak sale hl assum front-
line peak market share patient advanc stage diseas patient no-off label use
limit stage second line patient also includ pos-adjust adcetri peak
sale well peak us sale ctcl peak sale
indic adcetri compendia list adcetri current contribut pt
disappoint adcetri uptak advanc hl patient peak penetr well e-
failur would lower bear case scenario bull case scenario success strong
uptak adcetri base would result valuat adcetri
growth late stage pipelin key valu driver sgen emerg portfolio matur
agent enter pivot develop recent announc monotherapi
pivot phase ii trial enfortumab vedotin ev metastat urotheli cancer dose first
patient plan phase ib studi evalu ev combin inhibitor potenti
set stage futur front-lin phase trial management reiter plan initi pivot phase ii
studi tisotumab vedotin tv cervic cancer triple-neg breast cancer tnbc
move toward develop combin either tecentriq roch collabor
keytruda mp collabor three agent current contribut combin
valuat use po adjust estim singl agent set
addit de-risk form combin data could increas wherea
unforeseen safeti issu one agent albeit unlik would result downsid valuat
earli stage pipelin key long-term valu driver current addl program earli
clinic develop intrigu multipl myeloma program
phase well two io agent first clinic
data program could emerg sgen earli stage pipelin current contribut
pt
rate outperform platform cellular metabol result semin
discoveri compani abl translat full array clinical-stag
pipelin asset target cancer orphan indic inborn error metabol
agio advanc candid idhifa ivosidenib next-
gener program first-in-class inhibitor mutant isocitr dehydrogenas
clinic valid r/r aml recent fda-approv
idhifa licens celg provid regulatori valid think
ww opportun agent front-lin aml could exceed bull-cas scenario
pend posit result on-going plan phase combin trial medacorp kol
spoke highlight good toler profil well strong mechanist ration
efficaci aml attribut support commerci uptak believ aml
opportun alon support upsid current valuat compani gener
deep portfolio innov first-in-class program focus cancer metabol rare genet
diseas metabol immuno-oncolog repres sourc upsid longer term
compani close relationship collabor celgen contribut significantli
fund well regulatori clinic expertis think bode well probabl
success pipelin program optimist top-tier management team abil
deliv long-term sharehold valu
price target share base dcf analysi
discount rate termin growth rate valu idh inhibitor idhifa
ivosidenib front-lin relapsed/refractori aml probabl adjust
po respect also model po pk-r activ pyruv
kinase-r defici addit factor agio cash well probability-weight
mileston payment celg
face commerci competit well regulatori risk product candid
platform like mani development earli commerci stage compani
also face manufactur competit commerci regulatori safeti risk well risk
intellectu properti risk manag execut specif risk relat fact
pipelin program first-in-class pose uniqu scientif clinic develop
rate arri share market perform arri current stock price fairli valu
view base late stage clinic pipelin consist proprietari mek braf
inhibitor binimetinib encorafenib respect partner selumetinib mek inhibitor
azn mp base analysi due dilig medacorp kol believ
binimetinib/encorafenib differenti current approv mek/braf inhibitor
mek/braf inhibitor market competit agent approv novarti nv mp
roch well entrench clinic practic particular novarti trametinib/dabrafenib
compel follow-on opportun binimetinib/encorafenib ph trial expect
complet think current valuat reflect bullish commerci scenario
binimetinib/encorafenib forecast conserv vs street consensu estim
absenc major valu inflect point next month expect stock
valu arri share month base discount cash flow analysi
use discount rate termin growth rate appli probability-adjust forecast
binimetinib encorafenib selumetinib royalti
earli stage biotech compani arri face signific clinic regulatori develop
risk well commerci risk arri also face execut risk financi risk
compani may addit financ need turn cash flow posit
rate outperform pt base probability-adjust dcf
analysi rubraca one lead parp inhibitor develop main near-
term valu driver drug current approv us therapi line ovarian
cancer patient brca biomark posit product launch
commerci potenti rubraca indic moder believ rubraca
signific commerci potenti indic current fulli reflect
valuat includ earlier line ovarian cancer therapi prostat cancer breast
gastroesophag cancer potenti other among approv launch
line ovarian cancer mainten repres import near-term valu driver follow
first clinic result trial prostat cancer expect ultim
see compel target given broad potenti rubraca across variou
indic combin agent
price target valuat deriv dcf-base analysi
incorpor probability-adjust sale rubraca ovarian cancer well indic
trial on-going plan prostat bladder breast use wacc discount
rate termin growth rate post patent expir compar similar
compani coverag
face commerci competit well regulatori risk rubraca like mani
development earli commerci stage compani also face manufactur
competit commerci regulatori safeti risk well risk intellectu properti
risk manag execut
rate share market perform think street consensu estim adequ
reflect commerci potenti cabometyx rcc current valuat impli
addit valu key near-term label extens opportun rcc liver cancer
price construct long-term potenti cabometyx
combin immune-checkpoint inhibitor indic think next catalyst
approach hand share may face headwind next
month exampl driven addl uncertainti evolv rcc market riskier
pipelin event near term cotel trial
price target base discount cash flow sum-of-part analysi use
wacc discount rate well termin growth rate appli cash flow post
anticip product patent expir
risk includ abil continu grow product sale also face clinic
regulatori risk sinc main valu driver current multipl on-going clinic trial
regulatori review like mani biopharma compani also face manufactur
competit commerci regulatori safeti risk well risk intellectu properti
outperform thesi driven three factor expect consensu growth
jakafi ruxolitinib long term view risk/reward inci ido inhibitor epacadostat
skew upsid expect long-term valu creation deep
pipelin oncolog creat sever addit shot goal
one-year price target pt base discount cash flow sum-of-part
analysi use wacc discount rate view appropri
commerci mid-cap biotech compani termin growth rate
post-pat expir market generic
face commerci competit well regulatori risk jakafi like mani
commerci regulatori safeti risk well risk intellectu properti
rate op price target despit recent strong stock perform
share still trade discount oncolog peer think due commerci
concern around compani lead product neratinib nerlynx success
complet phase develop patient earli breast cancer obtain
fda-approv juli recent interview medacorp breast cancer specialist
follow present roch aphin trial result well analysi
breast cancer market indic commerci potenti drug may larger
impli compani current valuat
price target valuat deriv dcf-base analysi
incorpor forecast neratinib nerlynx sale adjuv metastat breast
cancer treatment use wacc discount rate termin growth rate post
patent expir expect compar similar compani coverag
face commerci competit well regulatori risk neratinib nerlynx like
mani development earli commerci stage compani also face
manufactur competit commerci regulatori safeti risk well risk
intellectu properti risk manag execut
rate share seattl genet outperform believ antibodi drug conjug
technolog foundat import platform
valid clinic data intern extern candid solid blood cancer
lead product adcetri highli activ agent relaps refractori hodgkin lymphoma
hl express target larg number hematolog cancer beyond hl
combin clinic valid activ agent creat high probability-of-success
label expans opportun current pursu address potenti
us peak opportun adcetri proprietari earli stage pipelin
view becom interest well extern collabor pipelin shown
promis could provid long-term upsid compani antibody-drug conjug
toolbox product engin creat multipl proprietari partner shot
goal compani recent expans treatment modal extern busi
develop activ could offer addit diversif longer term base exampl
two approv adc adcetri kadcyla review avail data adc
believ adc among best valid novel drug develop platform among
like reproduc gener addit success drug generic
agent could difficult
price target base-cas valuat deriv dcf-base
analysi probability-adjust sale adcetri enfortumab vedotin tisotumab vedotin
earli stage pipelin dcf analysi use wacc consist
commerci stage compani coverag
risk valuat seattl genet includ uncertainti size commerci
potenti adcetri clinic risk addit indic still-limit safeti experi
remain regulatori execut risk adcetri pipelin candid
 mm except per share data
total net
net incom tax
bs/cf mm
sec file leerink partner estim
chang
sec file leerink partner estim
arri mm
licens mileston revenu
partner program
regain binimetinib
total expens
arri bs cf mm
chang
oper
invest
financ
sec file leerink partner estim
 mm except per share data
licens mileston revenu
total net
net incom tax
bs/cf mm
chang
sec file leerink partner estim
licens contract revenu
total cost expens
interest incom net
loss extinguish debt
incom tax
chang
oper
invest
financ
compani file leerink partner estim
 mm except ep
product revenu
chang fair valu acquisition-rel conting consider
total incom expens
bs cf mm
sec file leerink partner estim
chang
oper
invest
financ
sec file leerink partner estim
 mm except per share data
net incom tax
bs/cf mm
chang
sec file leerink partner estim
 mm except ep
collabor licens agreement revenu
royalti revenu
bs cf mm
chang
oper
invest
financ
sec file leerink partner estim
